Braveheart Bio (BRVE) 10% Owner Jiangsu Hengrui Converts Shares

What Happened
Jiangsu Hengrui Pharmaceuticals Co., Ltd., reported as a 10% owner of Braveheart Bio (BRVE), converted derivative/preferred securities into common stock on 2026-08-07. The filing shows two conversion entries totaling 39,920,091 common shares (7,420,091 acquired in one entry and 32,500,000 recorded as a disposition of a derivative security). Both conversions are non‑cash transactions and are reported with no cash proceeds ($0.00).

Key Details

• Transaction date: 2026-08-07; Form 4 filed: 2026-08-10 (timely).
• Reported transactions: conversion of derivative securities (transaction code C).
  • +7,420,091 shares (Acquired; price N/A)
  • 32,500,000 shares (Disposed; reported price $0.00)
• Total shares converted on the date: 39,920,091 common shares.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The filer’s Series A non‑voting preferred stock is convertible into common at holder election and had an automatic conversion immediately prior to the company’s IPO (see footnote F1).
• This filing reflects an institutional conversion by a 10% owner, not an open‑market buy or sell.

Context

• Conversion of preferred or other derivative securities into common stock is a non‑cash reclassification; $0 proceeds are typical and do not indicate a market sale.
• As a 10% institutional holder, Jiangsu Hengrui’s conversion is corporate/ownership-related and should be interpreted differently from executive insider buys or sells.